Determining the critical quality attributes (CQAs) of emerging, more complex nucleic acid (NA) therapeutics and their carrier systems poses a new challenge for biopharmaceutical companies. Low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results